TCRT Stock Explodes As Velaris Deal And Cash Raise Reset The Story

Alaunos Therapeutics Inc. stocks have been trading up by 16.35 percent amid optimism over its latest targeted T-cell therapy developments.

Live Update At 09:18:24 EDT: On Monday, October 19, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 16.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT has transformed from a quiet micro-cap into a momentum biotech name almost overnight. The daily chart tells the story. Alaunos Therapeutics closed at $1.05 on 2026/10/12. One day later, as the Velaris Therapeutics deal and $350M private placement hit the tape, TCRT ripped to a $3.03 close after touching $4.32 intraday. Even after heavy profit-taking, the stock still finished 2026/10/16 at $2.63, far above its sub‑$1 base.

Under the hood, Alaunos Therapeutics remains an early‑stage, cash‑burning biotech. Quarterly revenue is only about $5,000, and key margins are deeply negative, with a pretax profit margin near ‑3,348%. TCRT posted roughly ‑$0.41 in basic EPS for the latest quarter, with operating cash flow around ‑$300,000. The balance sheet shows just $124,000 in cash at period end and a tight current ratio of 0.8, underscoring why the $350M raise is so critical.

Valuation is extreme on traditional metrics. Price‑to‑sales near 957 and price‑to‑book around 3 show the market is paying for future optionality, not current fundamentals. For traders, that means TCRT is a pure sentiment and catalyst vehicle, not a value play.

Why Traders Are Watching TCRT Now

TCRT is suddenly on every momentum trader’s screen because the narrative flipped in a matter of days. Alaunos Therapeutics didn’t just buy another tiny biotech. By closing the Velaris Therapeutics acquisition, TCRT picked up a pipeline of ActRII‑Fc ligand traps and other biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. That gives the company a clear therapeutic focus and, more importantly, multiple shots on goal.

The $350M private placement is the second part of the story. Before this raise, Alaunos Therapeutics was scraping by with six‑figure cash and negative working capital. Now, management says the new capital extends the runway into 2029 and can carry several candidates, including VLR199, through proof‑of‑concept and early regulatory filings. For traders, that matters. A longer runway reduces near‑term financing risk and sets up a series of clinical catalysts that can spark future trading waves.

The market reaction shows how quickly sentiment can reset. On the back of the Velaris deal and Series C non‑voting convertible preferred stock offering, TCRT shares exploded higher, with different reports pegging the surge between about 126% and roughly 225%, all on extremely heavy volume. That type of volume tells you real money and fast money piled in at the same time.

Then came the governance twist. Alaunos Therapeutics popped another 35% after SEC filings revealed Fairmount Funds grabbed a 19.99% stake and wants four of five board seats. That is effectively a bid for control. Traders should read that as a signal that an engaged shareholder believes TCRT’s new pipeline and extended cash runway justify a more aggressive strategic push.

Conclusion

Alaunos Therapeutics has turned into a classic case study of how small‑cap biotech can go from forgotten to front‑page on a few headlines. The Velaris Therapeutics acquisition handed TCRT a cardiopulmonary pipeline with real scientific ambition, anchored by VLR199 for pulmonary arterial hypertension. The $350M private placement reset the balance sheet and, on paper, funds operations into 2029. Together, those moves gave traders a cleaner story and removed near‑term survival worries.

Price action confirms just how dramatic the reset has been. TCRT blasted off from around $1 to intraday highs above $4.40, then settled into the mid‑$2s with wide intraday swings. The intraday 5‑minute chart shows repeated pushes above $3 followed by sharp pullbacks, a textbook volatility playground for short‑term traders. At the same time, Fairmount Funds stepping in for 19.99% of Alaunos Therapeutics and seeking board control adds a layer of potential corporate drama that markets love to trade.

For anyone studying this move, the key is discipline. This is a story‑driven biotech with tiny revenue, heavy losses, and now a huge cash pile earmarked for clinical risk. That makes emotional decision‑making especially dangerous for anyone trading this ticker. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. As Tim Sykes likes to remind his students, “The market rewards preparation, not hope — you win by planning every trade and cutting losses fast.” TCRT fits that mindset perfectly: high reward potential, high volatility, and no room for sloppy trading. This article is for educational and research purposes only and should not be taken as investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks